Ritanserin, a Selective 5-HT2/1C Antagonist, and Negative Symptoms in Schizophrenia

1993 ◽  
Vol 163 (4) ◽  
pp. 451-455 ◽  
Author(s):  
S. J. Duinkerke ◽  
P. A. Botter ◽  
A. A. I. Jansen ◽  
P. A. M. Van Dongen ◽  
A. J. Van Haaften ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Statistical Significance ◽  
Depressive Mood ◽  
Neuroleptic Treatment ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Trial Treatment ◽  
Schizophrenic Patients ◽  
Specific Symptoms

The effectiveness of ritanserin, a selective 5-HT2 and 5-HT1c antagonist, in reducing negative symptoms in schizophrenia was investigated in a double-blind, placebo-controlled trial. Trial treatment was added to a stable neuroleptic treatment in 33 schizophrenic patients with predominantly negative symptoms. Ritanserin reduced the negative symptoms, as measured with the SANS. The main reduction was for the items facial expression, global affective flattening, and relationships with friends and peers. Also a reduction in total BPRS score was found, which approached statistical significance. Significant reductions were observed for the BPRS items emotional withdrawal and depressive mood. Ritanserin or other drugs blocking 5-HT2 and/or 5-HT1c receptors could be important in reducing specific symptoms in schizophrenic patients.

Late Phase Inflammation during Nasal Grass and Ragweed Challenge in a Double-Blind Placebo Controlled Trial with Astemizole

1995 ◽  
Vol 9 (3) ◽  
pp. 169-174 ◽  
Author(s):  
Marianne Frieri ◽  
James Madden ◽  
Myron Zitt ◽  
Nanjundaiah S. Kumar ◽  
Maria Knapik
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Congestion ◽  
Controlled Trial ◽  
Statistical Significance ◽  
Interleukin 1 ◽  
Late Phase ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Nasal Provocation ◽  
Anti Inflammatory

Allergic rhinitis is an IgE-mediated inflammatory reaction characterized by an early “classic” immediate hypersensitivity response and/or a subsequent late phase response. Nasal provocation to antigen challenge is a useful method of evaluating this dual response. Several H1 antagonists may exhibit antiinflammatory properties by diminishing histamine release or inhibiting eosinophil chemotaxis. To determine whether astemizole has any anti-inflammatory characteristics, we studied 20 patients with allergic rhinitis in a double-blind placebo-controlled fashion after a 4-week course of treatment with this H1 antagonist. Nasal provocation over 30 minutes was performed out of season using increasing concentrations of grass or ragweed extract from 10–1000 PNU. Patients were evaluated for their clinical response, and nasal lavage secretions were analyzed over 6 hours by ELISA for alpha interleukin-1, interleukin-8, albumin, and histamine levels. Total sneezing and other symptom scores for rhinorrhea, nasal congestion, and pruritus were decreased in astemizole-treated compared to placebo-treated patients both at 30 minutes (early phase), and at 3 and 6 hours (late phase) after nasal provocation. However, these results did not reach statistical significance. Nasal α IL-1 levels diminished from diluent control lavage to a significantly greater degree in astemizole than in placebo-treated patients (P < 0.05). This diminution in late phase α IL-1 suggests that astemizole may possess anti-inflammatory properties.

Cariprazine in Negative Symptoms of Schizophrenia: Post-hoc Analyses of a Fixed-dose Phase Iii, Randomized, Double-blind, Placebo- and Active-controlled Trial

2015 ◽  
Vol 30 ◽  
pp. 242 ◽  
Author(s):  
M. Debelle ◽  
S. Faradzs-zade ◽  
B. Szatmari ◽  
K. Nagy ◽  
G. Nemeth ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Phase Iii ◽  
Fixed Dose ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Post Hoc

Brain imaging to determine the effects of sertindole in a double-blind, placebo-controlled trial in schizophrenic patients

1996 ◽  
Vol 18 (2-3) ◽  
pp. 201-202
Author(s):  
S. Potkin ◽  
J. Zborowski ◽  
J. Wu ◽  
K. Giles ◽  
R. Bera ◽  
...  
Keyword(s):  
Brain Imaging ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Schizophrenic Patients

scholarly journals The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial

2018 ◽  
Vol 5 (11) ◽  
pp. 885-894 ◽  
Author(s):  
Bill Deakin ◽  
John Suckling ◽  
Thomas R E Barnes ◽  
Kelly Byrne ◽  
Imran B Chaudhry ◽  
...  
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Recent Onset

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1983 ◽  
Vol 143 (2) ◽  
pp. 151-155 ◽  
Author(s):  
C. R. Pugh ◽  
J. Steinert ◽  
R. G. Priest
Keyword(s):  
Beneficial Effect ◽  
Recent Work ◽  
Controlled Trial ◽  
Pharmacokinetic Interaction ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

SummaryA double blind, placebo controlled trial was carried out to examine the contribution of propranolol as an adjunct to neuroleptic medication in the treatment of chronic schizophrenic patients whose florid symptoms had not remitted with neuroleptic medication alone. Propranolol was shown to have a more beneficial effect than placebo, but the results were much less dramatic than those which have been described in previous studies. Recent work has shown that there may be a pharmacokinetic interaction between propranolol and neuroleptics, and this should be considered as one possible explanation of our findings.

A Randomized, Double-Blind, Placebo-Controlled Trial of Modafinil for Negative Symptoms in Schizophrenia

2007 ◽  
Vol 68 (05) ◽  
pp. 705-710 ◽  
Author(s):  
Joseph M. Pierre ◽  
John H. Peloian ◽  
Donna A. Wirshing ◽  
William C. Wirshing ◽  
Stephen R. Marder
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Amisulpride Augmentation Therapy Improves Cognitive Performance and Psychopathology in Clozapine-resistant Treatment-refractory Schizophrenia (CTRS): a 12-week Randomized, Double-blind, Placebo-controlled Trial

2022 ◽  
Author(s):  
Zezhi Li ◽  
Minghuan Zhu ◽  
Zhenjing Liu ◽  
Qiongyue Hu ◽  
Jiayu Yang ◽  
...  
Keyword(s):  
Placebo Group ◽  
Cognitive Function ◽  
Cognitive Performance ◽  
Negative Symptoms ◽  
Psychiatric Symptoms ◽  
Controlled Trial ◽  
Augmentation Therapy ◽  
Laboratory Measurements ◽  
Double Blind ◽  
Double Blind Placebo

Abstract BackgroundAlthough clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main purposes of this randomized, double-blind, placebo-controlled trial was to explore the amisulpride augmentation efficacy on the psychopathological symptoms and cognitive function of CTRS patients. MethodsA total of 80 patients were recruited and randomly assigned to receive an initial clozapine plus amisulpride or clozapine plus placebo. Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Clinical Global Impression (CGI) scale scores, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Treatment Emergent Symptom Scale (TESS), laboratory measurements and electrocardiograms (ECG) were performed at baseline, week 6, and week 12. ResultsCompared with clozapine plus placebo group, clozapine plus amisulpride had lower PANSS total score, positive subscore and general psychopathology subscore at week 6 and week 12 (all p Bonferroni< 0.01). Furthermore, compared with clozapine plus placebo group, clozapine plus amisulpride showed improved RBANS language score at week 12 (p Bonferroni< 0.001). Clozapine plus amisulpride group had a higher treatment response rate (p = 0.04), lower scores of CGI severity (CGI-S) and CGI efficacy (CGI-E) at week 6 and week 12 than clozapine plus placebo (all p Bonferroni< 0.05). There were no differences in BMI, QT intervals or laboratory measurements between the groups. Our results demonstrate that amisulpride augmentation therapy can safely improve the psychiatric symptoms and cognitive performance of CTRS patients. ConclusionsOur study indicates that amisulpride augmentation therapy has important clinical significance for the treatment of CTRS to improve clinical symptoms and cognitive function with tolerability and safety.Trial registrationClinicaltrials.gov identifier- NCT03652974. Registered 31 August 2018, https://clinicaltrials.gov/ct2/show/NCT03652974

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial

2010 ◽  
Vol 179 (1) ◽  
pp. 19-23 ◽  
Author(s):  
Iulian Iancu ◽  
Eleonora Tschernihovsky ◽  
Ehud Bodner ◽  
Anna Sapir Piconne ◽  
Katherine Lowengrub
Keyword(s):  
Negative Symptoms ◽  
Controlled Trial ◽  
Chronic Schizophrenia ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document